Supplementary Content.docx (401.41 kB)

Cost–effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer . Supplementary Content

Name: Cost–effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer . Supplementary Content
Published: 2023-07-26T07:25:36+00:00
License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: camrelizumab, chemotherapy, cost–effectiveness, partitioned survival model, squamous non-small cell lung cancer